Ccn5 Antibody

What is the molecular basis for selecting appropriate CCN5 antibodies for experimental procedures?

When selecting CCN5 antibodies for research, researchers should consider the specific molecular characteristics of CCN5 protein. CCN5 has a calculated molecular weight of approximately 27 kDa and is localized in both the cytoplasm and nucleus of breast cancer cells . For optimal antibody selection, consider:

• Validated reactivity with human, mouse, or rat CCN5 depending on your experimental model

• Confirmed application compatibility (ELISA, Western blot, IHC, or IF/ICC)

• Recognition of specific epitopes (e.g., antibodies targeting amino acids 164-250 of human WISP2 have been successfully used)

• Clonality preference (polyclonal antibodies offer broader epitope recognition while monoclonal provides greater specificity)

For confocal microscopy applications, antibodies from Santa Cruz Biotechnology have been successfully utilized in conjunction with FITC-conjugated secondary antibodies to visualize CCN5 localization in MCF-7 cells .

How does subcellular localization of CCN5 impact experimental design and interpretation?

CCN5 exhibits distinctive subcellular localization patterns that should influence experimental design considerations:

• CCN5 is present in both cytoplasmic and nuclear compartments of breast cancer cells

• Confocal immunofluorescence microscopy reveals CCN5 in discrete nuclear structures in addition to cytoplasmic staining

• Cell fractionation followed by Western blot analysis confirms the dual localization without cross-contamination between compartments

When designing experiments, researchers should:

• Include appropriate subcellular fraction controls (e.g., GAPDH for cytoplasm, lamin A/C for nucleus) to verify compartment purity

• Use confocal microscopy with z-stack capability to accurately distinguish nuclear from cytoplasmic staining

• Consider dual-staining approaches to correlate CCN5 localization with functional partners like HDAC1

• Interpret results in the context of this dual localization, as nuclear CCN5 may relate to its transcriptional repressor functions while cytoplasmic CCN5 might reflect its role in signaling pathways

What are the standard protocols for CCN5 detection in clinical breast cancer specimens?

For clinical specimen analysis, standardized protocols for CCN5 detection include:

Immunohistochemistry (IHC) procedure:

• Treatment with 3% H₂O₂ for 10 minutes to block endogenous peroxidase

• Primary CCN5 antibody incubation at 4°C overnight

• Secondary antibody incubation at room temperature for 18 minutes

• DAB reagent application for color development

• Counterstaining, dehydration, and sealing with neutral balsam

Scoring system for CCN5 expression:

• Staining intensity scoring: No staining (0), light yellow (1), brownish yellow (2), brown (3)

• Percentage of positive cells scoring: <5% (0), 5-25% (1), 25-50% (2), 50-75% (3), >75% (4)

• Total score calculation: Sum of intensity and percentage scores

• Interpretation: Total score ≤3 considered negative; >3 considered positive

This standardized approach allows for objective assessment of CCN5 expression levels in breast cancer tissues and facilitates comparison across studies .

How can ChIP assays be optimized to investigate CCN5's role in transcriptional regulation?

Chromatin immunoprecipitation (ChIP) assays are crucial for understanding CCN5's function as a transcriptional repressor. Based on published protocols:

• Cross-linking and chromatin preparation:

  • Save 1% of cross-linked, sheared chromatin as input DNA control

  • Use specific antibodies against CCN5 (Santa Cruz Biotechnology) for immunoprecipitation

  • Include parallel IPs with antibodies against acetylated H3, acetylated H4, HDAC1, or Sp1 to provide mechanistic insights

• DNA analysis:

  • Deproteinize and ethanol-precipitate immunoprecipitated DNA

  • Resuspend in 30 μl water

  • Use 2 μl for PCR amplification (30 cycles)

  • For TGF-βRII gene promoter analysis, use specific primers:

    • Upper: 5′-GGAGCAATCTGAAGAAAGCTGA-3′

    • Lower: 5′-GGGGAAACAGGAAACTCCTC-3′

• Controls and validation:

  • Include IgG negative controls

  • Use known CCN5-regulated genes like TGF-βRII as positive controls

  • Validate findings with reporter gene assays to confirm functional significance

This methodology has successfully demonstrated CCN5 recruitment to the TGF-βRII promoter, providing mechanistic explanation for CCN5's ability to restrict transcription of this gene .

What experimental approaches can elucidate the relationship between CCN5 and epithelial-mesenchymal transition (EMT)?

To investigate CCN5's role in regulating EMT, the following experimental approaches are recommended:

• Gene expression analysis:

  • Microarray analysis comparing CCN5-expressing vs. CCN5-depleted cells to identify EMT-associated genes regulated by CCN5

  • RT-qPCR validation of key EMT markers (E-cadherin, vimentin, N-cadherin) in response to CCN5 manipulation

• Protein interaction studies:

  • Co-immunoprecipitation to detect CCN5 interaction with HDACs and other chromatin modifiers

  • Proximity ligation assays to visualize protein interactions in situ

• Functional assays:

  • Invasion assays to assess CCN5's effect on TGF-β-induced EMT

  • Migration assays to quantify cell motility changes in response to CCN5 expression

  • 3D organoid cultures to evaluate morphological changes associated with EMT

• Dual immunohistochemistry:

  • Simultaneous detection of CCN5 and E-cadherin in breast cancer tissues

  • Scoring system as described previously to evaluate correlation between these markers

This multi-faceted approach has revealed that CCN5 suppresses TGF-β-induced transcriptional responses and invasion concomitant with EMT, supporting its role as an EMT inhibitor .

How should researchers interpret contradictory data regarding CCN5 expression in different breast cancer stages?

When confronted with seemingly contradictory data on CCN5 expression, researchers should consider:

• Tumor heterogeneity factors:

  • Primary versus recurrent lesions show significantly different CCN5 expression patterns (higher in primary lesions)

  • Lymph node metastasis status correlates with CCN5 expression (higher in non-metastatic cases)

  • Histological subtypes may exhibit variable expression patterns

• Methodological considerations:

  • Antibody specificity and epitope accessibility

  • Sample preparation techniques affecting antigen retrieval

  • Scoring system standardization across studies

• Statistical analysis approach:

  • Use non-parametric tests for comparing CCN5 expression between tissues

  • Apply Spearman's correlation for analyzing relationships between CCN5 and other markers

This table illustrates the significant differences in CCN5 expression across normal, primary, and recurrent breast cancer tissues, highlighting the importance of context when interpreting expression data .

What are the optimal antibody dilutions and technical parameters for different CCN5 detection methods?

Based on validated research protocols, the following technical parameters should be considered:

Key technical considerations:

• Buffer composition for protein extraction: 20 mM Tris-HCl pH 7.2, 10% glycerol, 150 mM NaCl with protease inhibitors (0.5 mM PMSF, 1 μM leupeptin, 1 μM aprotinin)

• Protein loading: 50 μg for optimal detection in Western blot applications

• Antibody storage: Aliquot and store at -20°C; avoid repeated freeze/thaw cycles

• Visualization systems: Horseradish peroxidase-conjugated secondary antibodies for Western blot; fluorophore-conjugated antibodies for IF/ICC

These parameters should be optimized for specific experimental conditions and validated using appropriate controls.

How can researchers optimize protocols to detect both cytoplasmic and nuclear CCN5 fractions?

To accurately detect and distinguish between cytoplasmic and nuclear CCN5 fractions:

• Cell fractionation protocol:

  • Use validated subcellular fractionation kits or established protocols

  • Include control antibodies for fraction purity verification:

    • Cytoplasmic marker: GAPDH

    • Nuclear markers: Lamin A and C

• Confocal microscopy optimization:

  • Fix cells with 4% paraformaldehyde in PBS

  • Permeabilize with 0.1% Triton X-100 in PBS

  • Block with appropriate blocking buffer

  • Incubate with primary CCN5 antibody (Santa Cruz Biotechnology)

  • Apply FITC-conjugated secondary antibody (goat anti-rabbit)

  • Counterstain nuclei with DAPI (1 μg/ml)

  • Image using confocal microscopy (e.g., Leica SP2 biphoton laser scanning)

• Immunohistochemistry considerations:

  • Optimize antigen retrieval conditions to expose both nuclear and cytoplasmic epitopes

  • Employ counterstaining that allows clear distinction between compartments

  • Develop separate scoring criteria for nuclear versus cytoplasmic staining

  • Consider dual immunofluorescence with compartment-specific markers

This multi-method approach provides complementary data on CCN5's subcellular distribution, essential for understanding its dual functional roles in signaling and transcriptional regulation .

What experimental designs can best assess the functional relationship between CCN5 and p53 in breast cancer progression?

To investigate the functional relationship between CCN5 and mutant p53 in breast cancer:

• Expression correlation studies:

  • Perform dual immunohistochemistry for CCN5 and p53 in matched tissue samples

  • Compare expression patterns across normal, primary, and recurrent lesions

  • Apply statistical analysis to quantify negative correlation (rp=-0.013, P<0.001)

• Mechanistic investigations:

  • Employ gene silencing or overexpression approaches in appropriate cell lines

  • Assess how CCN5 manipulation affects p53 expression and activity

  • Identify potential shared regulatory pathways or direct interactions

• Clinical correlation design:

  • Stratify samples by lymph node metastasis status

  • Compare CCN5 and p53 expression patterns:

• Functional assays:

  • Migration and invasion assays following manipulation of CCN5 and/or p53

  • Monitor EMT marker expression changes when both factors are experimentally altered

  • Assess treatment response patterns in cells with various CCN5/p53 expression profiles

This experimental framework can help elucidate how CCN5 and p53 may play opposing regulatory roles in breast cancer recurrence and lymph node metastasis, contributing to tumor development and prognosis .

What are the common challenges in CCN5 antibody-based experiments and how can they be addressed?

Researchers frequently encounter several challenges when working with CCN5 antibodies:

• Specificity issues:

  • Challenge: Cross-reactivity with other CCN family members due to structural similarities

  • Solution: Validate antibody specificity using CCN5 knockout/knockdown controls; perform pre-absorption tests; use antibodies targeting unique CCN5 regions

• Signal intensity problems:

  • Challenge: Weak or variable staining intensities in IHC/ICC applications

  • Solution: Optimize antigen retrieval methods; adjust antibody concentration; extend incubation times; employ signal amplification systems

• Nuclear epitope accessibility:

  • Challenge: Difficulty detecting nuclear CCN5 fraction

  • Solution: Ensure adequate nuclear membrane permeabilization; use heat-induced epitope retrieval; try different fixation protocols

• Quantification inconsistencies:

  • Challenge: Subjective scoring of CCN5 positivity in clinical samples

  • Solution: Implement standardized scoring system combining intensity and percentage metrics; use digital image analysis; employ multiple independent scorers

• Reproducibility concerns:

  • Challenge: Variation between experiments and laboratories

  • Solution: Document detailed protocols; maintain consistent antibody lots; include standard positive and negative controls in each experiment

Addressing these challenges through methodological optimization and rigorous controls enhances the reliability and reproducibility of CCN5 antibody-based research.

How can researchers validate CCN5 antibody specificity in their experimental systems?

To ensure CCN5 antibody specificity and experimental validity:

• Multiple antibody validation approaches:

  • Western blot analysis confirming the expected 27 kDa molecular weight band

  • Peptide competition assays to demonstrate binding specificity

  • Parallel staining with different antibodies targeting distinct CCN5 epitopes

  • Testing in positive control tissues/cells (e.g., MCF-7) and negative control samples (e.g., MDA-MB-231)

• Genetic validation methods:

  • siRNA/shRNA knockdown of CCN5 should reduce or eliminate antibody signal

  • Overexpression systems should show increased antibody signal intensity

  • CRISPR/Cas9 knockout controls provide definitive specificity confirmation

• Cross-reactivity assessment:

  • Test antibody against recombinant proteins of other CCN family members

  • Evaluate performance in tissues/cells with known CCN expression profiles

  • Consider using antibodies raised against unique regions of CCN5 structure

• Method-specific validation:

  • For ChIP assays: Include IgG controls and input DNA normalization

  • For IHC: Use isotype-matched control antibodies on serial sections

  • For ICC/IF: Include secondary-only controls to assess background

Thorough validation using multiple approaches ensures that experimental findings accurately reflect CCN5 biology rather than artifacts of non-specific antibody interactions.

How can CCN5 antibodies be utilized to study the protein's role in regulating the TGF-β signaling pathway?

CCN5 antibodies provide critical tools for investigating its role in TGF-β pathway regulation:

• ChIP-seq approach:

  • Use CCN5 antibodies for genome-wide chromatin immunoprecipitation followed by sequencing

  • Identify all genomic loci bound by CCN5, with particular focus on TGF-β pathway component genes

  • Validate findings through targeted ChIP-qPCR for specific promoters like TGF-βRII

• Co-immunoprecipitation studies:

  • Precipitate CCN5 protein complexes and analyze for TGF-β pathway components

  • Identify direct protein interactions that mediate CCN5's regulatory functions

  • Perform reciprocal co-IPs to confirm interactions

• Functional pathway analysis:

  • Manipulate CCN5 expression and measure TGF-β pathway activation markers

  • Assess expression of downstream targets like PAI1 through Western blot

  • Quantify phosphorylation of SMAD proteins as indicators of pathway activity

• Co-localization experiments:

  • Use dual immunofluorescence with CCN5 and TGF-β pathway component antibodies

  • Analyze subcellular co-localization patterns in response to pathway activation

  • Apply proximity ligation assays to confirm direct interactions in situ

These approaches have demonstrated that CCN5 restricts transcription of TGF-βRII and suppresses TGF-β-induced transcriptional responses, providing mechanistic insight into CCN5's role in inhibiting EMT and tumor invasion .

What emerging research directions are being explored using CCN5 antibodies in cancer research?

Current and emerging research directions utilizing CCN5 antibodies include:

• Predictive and prognostic biomarker development:

  • Correlating CCN5 expression patterns with treatment responses

  • Developing IHC-based scoring systems for patient stratification

  • Exploring the negative relationship between CCN5 and p53 as prognostic indicators

• Therapeutic target validation:

  • Using antibodies to identify and validate druggable domains or interactions

  • Monitoring changes in CCN5 expression in response to experimental therapeutics

  • Developing function-blocking antibodies targeting CCN5 extracellular domains

• Single-cell analysis approaches:

  • Applying antibodies in single-cell proteomics techniques

  • Mapping heterogeneity of CCN5 expression within tumors

  • Correlating with other markers at single-cell resolution

• Dynamic regulation studies:

  • Investigating temporal changes in CCN5 localization during disease progression

  • Examining redistribution between nuclear and cytoplasmic compartments in response to stimuli

  • Monitoring real-time changes using fluorescently tagged antibody fragments

• Liquid biopsy applications:

  • Exploring CCN5 detection in circulating tumor cells or exosomes

  • Correlating with tissue expression patterns and clinical outcomes

  • Developing minimally invasive monitoring approaches

These research directions leverage the specificity of CCN5 antibodies to advance understanding of breast cancer progression mechanisms and develop new clinical applications for diagnosis, prognosis, and treatment selection.